🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Wishing you a joyous Holiday Season!

Wishing you a Happy New Year!

Today LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., to Evaluate LAVA-1207 in Combination with KEYTRUDA® Read the full press release: bit.ly/3SaxLyF

On #InternationalDayofWomenandGirlsinScience, we recognize the importance of empowering women to put science to work for a sustainable future. To our employees working tirelessly towards the advancement of research for new cancer therapies: Thank you for your dedication!

Happy #EmployeeAppreciationDay to our amazing team at LAVA Therapeutics! Your hard work and dedication are critical to our research into potential new #cancer therapies, and we are grateful for everything you do.

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223) Read the full press release: bit.ly/3uVJiug

Thanking the @Pfizer Team for their support - looking forward to our continued collaboration on PF-08046052 (LAVA-1223)

Today we announced Fourth-quarter financial results and recent corporate highlights. Read the full press release: bit.ly/3Vl1kAV

Today we announced first-quarter financial results and recent corporate highlights. Read the full press release: bit.ly/4bPMKXb

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference. Read the full press release: bit.ly/4bW3ego

LAVA Announces Annual Meeting of Shareholders. Read the full press release: bit.ly/45fcpq5

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Read the full press release: bit.ly/4cuF9h2

At the H.C. Wainwright Immune Cell Engager Virtual Conference members of the LAVA management team participated in a fireside chat. Listen to Webcast here: bit.ly/3MasWR4

Today we announced second-quarter financial results and recent corporate highlights. Read the full press release: bit.ly/3XazQOZ

At the H.C. Wainwright 26th Annual Global Investment Conference, happening next week, Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat. Learn more: bit.ly/4cWArrX

Today, members of the LAVA management team participated in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference.  Watch here: bit.ly/3ZhRQYX

Today we announced third-quarter financial results and recent corporate highlights. Read the full press release: bit.ly/3BjMumE

Today we announced Fourth-quarter financial results and recent corporate highlights. Read the full press release: bit.ly/3DZOeTp

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation. Read the full press release: bit.ly/4jxSF6V

Today we announced first-quarter financial results and recent corporate highlights. Read the full press release: bit.ly/3FbMNlj